Eicosapentaenoic acid + docosahexaenoic acid
Outcomes
1Major ischemic events
no changein humans1
1 study
Major ischemic events
no changein humans1
Eicosapentaenoic acid + docosahexaenoic acid has no effect on major ischemic events in humans (12.0% vs. 12.2%; hazard ratio 0.99).
ReviewSTRENGTHmixed EPA/DHA formulation4 g/day
Omega-3 Fatty Acids in the Management of Cardiovascular Disease Prevention
Cardiovascular drugs and therapy8 Oct 2026
Latest
9 in 12 monthsCardiovascular Drugs and Therapy
Omega-3 Fatty Acids in the Management of Cardiovascular Disease Prevention
ReviewCardiovascular disease
Frontiers in Nutrition
A randomized parallel-designed study evaluating the effect of an app-based nutritional concept for weight reduction and further cardiovascular risk factors: Insights from the PreVA study
Randomised trial in 80 peopleInterventions
medRxiv
Age-related alterations in blood fatty acid composition and ratios, omega-3 fatty acid levels and association with PhenoAge acceleration: a cross-sectional analysis of the NHANES 2021-2023 data
Preprint: cross-sectional study of 4,863 peoplePopulations
Nutrition Research
The relationship between plasma long-chain fatty acids and hypertension and its underlying molecular mechanisms
Cross-sectional study of 2,092 peopleHypertension
Journal of Clinical Lipidology
Fish oil supplementation reduces the CERT2 risk score in adults with increased cardiometabolic risk: Findings from the MoKaRi trial
Randomised trial in peopleCardiometabolic risk
AAIC 2025 Abstract
Spatially distinct accretion of docosahexaenoic acid and eicosapentaenoic acid in a mouse model of Alzheimer's disease prior to plaque deposition
Experiments in animalsMechanisms
AAIC 2025 Abstract
Metabolome Wide Association Study of Serum DDE in Midlife Adults: Relevance to Prodromal ADRD
Study in peopleMechanisms